Current concepts in primary effusion lymphoma and other effusion-based lymphomas

Area of Science:

• Oncology
• Virology
• Hematology

Background:

• Primary effusion lymphoma (PEL) is a distinct, aggressive large B-cell neoplasm.
• PEL is associated with human herpes virus 8 (HHV8) and typically occurs in individuals with human immunodeficiency virus (HIV) infection or other immune deficiencies.
• PEL presents as an effusion without detectable tumor mass, often with diverse cell morphologies and a characteristic immunophenotype.

Purpose of the Study:

• To highlight the diagnostic challenges and essential criteria for identifying Primary Effusion Lymphoma (PEL).
• To differentiate PEL from other body cavity-based lymphomas, particularly those associated with Epstein-Barr virus (EBV).
• To emphasize the importance of accurate diagnosis for therapeutic strategies and patient prognosis.

Main Methods:

• Review of clinical and pathological features of PEL.
• Immunophenotypic analysis of PEL cells, including expression of CD45, lymphocyte activation, and plasma cell antigens.
• Genetic analysis to demonstrate B-cell genotype and detection of HHV8 and EBV genomes.

Main Results:

• PEL cells exhibit varied morphologies and a unique immunophenotype, often lacking typical B- and T-cell markers.
• Diagnosis requires demonstration of a B-cell genotype and detection of HHV8; EBV is frequently present.
• Distinguishing PEL from HHV8-negative, EBV-positive lymphomas is critical due to different therapeutic approaches and prognoses.

Conclusions:

• Accurate diagnosis of PEL, based on immunophenotype, genotype, and viral detection (HHV8), is essential.
• Differentiating PEL from similar lymphomas, like EBV-associated body cavity-based lymphomas, is critical for appropriate management.
• Correctly identifying PEL and related disorders impacts treatment decisions and patient outcomes.